NCT02099058
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 99 Years (Adult), Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Subject has known uncontrolled metastases to the central nervous system (CNS)
https://ClinicalTrials.gov/show/NCT02099058